We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ibalizumab‐uiyk as a bridge therapy for a patient with drug‐resistant HIV‐1 infection receiving chemotherapy: A case report.
- Authors
Dickter, Jana K.; Martin, Abigail L.; Ho, Stephanie; Ross, Justine A.; Shouse, Geoffrey P.
- Abstract
What is known and objective: Treatment for diffuse large B‐cell lymphoma (DLBCL) in persons with AIDS consists of chemotherapy alongside antiretroviral therapy (ART). To determine optimal HIV treatment, drug‐drug interactions, toxic effects and ART resistance must be considered. Case description: A 40‐year‐old man with drug‐resistant HIV and DLBCL initiating chemotherapy which had drug interactions with his ART. During chemotherapy, darunavir/cobicistat was held and ibalizumab‐uiyk was started to ensure he was on three active HIV medications. What is new and conclusion: Ibalizumab‐uiyk has no known drug‐drug interactions and may be used as bridge therapy for patients with drug‐resistant HIV undergoing chemotherapy.
- Subjects
THERAPEUTIC use of monoclonal antibodies; HIV infections; CANCER chemotherapy; HETEROCYCLIC compounds; DRUG resistance; B cell lymphoma; DARUNAVIR; DRUG interactions
- Publication
Journal of Clinical Pharmacy & Therapeutics, 2021, Vol 46, Issue 4, p1185
- ISSN
0269-4727
- Publication type
Article
- DOI
10.1111/jcpt.13411